LYRA - Lyra Therapeutics: An Intriguing Risk/Reward Proposition Tackling Chronic Rhinosinusitis

• Lyra is to report top line data of its Phase 2 Trial in December.
• All indications are the trial should be a success, and they have strong backing from Perceptive Advisors.
• The market isn't paying much attention to the company at present, but good data would bring new investors.
• There is a long way to go to approval, but potential peak sales for Lyra are multiples of the current enterprise value.
• The company's current value is underpinned significantly by its robust balance sheet.

For further details see: